Sign in

You're signed outSign in or to get full access.

MR

Monte Rosa Therapeutics, Inc. (GLUE)·Q3 2025 Earnings Summary

Executive Summary

  • Q3 2025 collaboration revenue was $12.77M, up 38% year over year (vs. $9.22M in Q3 2024) but down sequentially from $23.19M in Q2; GAAP net loss was $27.08M as R&D spend stepped up with multiple programs advancing .
  • Results beat Wall Street: revenue beat consensus by ~73% ($12.77M vs. $7.37M*) and EPS beat by ~$0.02 (-$0.33* vs. -$0.35*), driven by higher-than-modeled collaboration revenue recognition pace; no non-GAAP metrics were provided (company reports GAAP only) .
  • Strategic update: a second Novartis collaboration delivered a $120M upfront (Sept) with total potential deal value up to $5.7B (options, milestones, royalties); non-current deferred revenue rose sharply, signaling significant future revenue recognition .
  • Liquidity extended: cash, cash equivalents, restricted cash, and marketable securities rose to $396.2M at 9/30/25; management now guides cash runway “through 2028,” supported by the $120M upfront and an October ATM raise (~$25.0M gross) .
  • Pipeline catalysts: MRT-2359 additional results targeted by year-end 2025; MRT‑8102 Phase 1 initial readout (including high-CVD risk cohort) on track for H1 2026; MRT‑6160 progressing toward multiple Phase 2 starts under Novartis leadership .

What Went Well and What Went Wrong

  • What Went Well

    • Material revenue/EPS beats vs. Street (revenue +73% vs. consensus; EPS ~$0.02 ahead), reflecting stronger collaboration revenue recognition than modeled .
    • Strategic validation and funding: second Novartis agreement added $120M upfront (Sept) with up to $5.7B total potential economics; cash runway extended through 2028 .
    • Portfolio execution: NEK7-directed MRT‑8102 Phase 1 underway (elevated CVD-risk cohort dosing initiated); VAV1-directed MRT‑6160 advancing toward multiple Phase 2 studies with Novartis; MRT‑2359 expansion in mCRPC continues with additional results expected by year-end 2025 .

  • What Went Wrong

    • Sequential top-line decline: collaboration revenue fell to $12.77M from $23.19M in Q2 as recognition cadence varied quarter-to-quarter with program progress .
    • OpEx intensity: R&D rose to $36.68M (vs. $30.65M in Q2 and $27.62M YoY) as clinical and preclinical portfolios scaled, driving a wider net loss of $27.08M (vs. $12.30M in Q2) .
    • Limited new clinical efficacy disclosures in the quarter; MRT‑2359 efficacy update remains a near-term catalyst (year-end timing), while MRT‑8102 clinical readout is H1 2026, leaving a multi-quarter wait for de-risking data .

Management quote: “Our recently announced second collaboration with Novartis marks another major milestone… Our cash runway extends beyond multiple anticipated Phase 2 readouts for MRT‑8102, MRT‑6160, and MRT‑2359” .

Financial Results

Metric (USD)Q3 2024Q1 2025Q2 2025Q3 2025
Collaboration Revenue ($ Millions)$9.216 $84.929 $23.194 $12.768
Research & Development Expense ($ Millions)$27.616 $32.190 $30.653 $36.678
General & Administrative Expense ($ Millions)$8.127 $8.703 $8.095 $9.065
Net Income (Loss) ($ Millions)$(23.859) $46.885 $(12.295) $(27.081)
Interest Income ($ Millions)$2.892 $3.439 $3.068 $2.746

KPIs and Balance Sheet

KPI (USD)Q1 2025Q2 2025Q3 2025
Cash, Cash Equivalents, Restricted Cash, and Marketable Securities ($ Millions)$331.0 $295.5 $396.2
Current Deferred Revenue ($ Millions)$32.575 $18.410 $24.791
Deferred Revenue, Non‑current ($ Millions)$16.863 $8.059 $111.894
ATM Offering (Shares/Proceeds)——2,955,082 shares sold in Oct 2025 for $25.0M gross / $23.9M net

Q3 2025 Actuals vs S&P Global Consensus

MetricConsensusActualSurprise
Revenue ($)$7,371,430*$12,768,000 +$5,396,570 / +73.2%
EPS (Primary)-$0.3525*-$0.33*+$0.02

Values with asterisks (*) retrieved from S&P Global.

Context and drivers:

  • Collaboration revenue represents amounts earned from Roche and Novartis agreements; non-current deferred revenue jumped to $111.9M at 9/30/25, consistent with the $120M upfront from the second Novartis deal in September 2025 .
  • R&D growth reflects advancement of MRT‑8102 into the clinic, ongoing MRT‑2359 evaluation, pre-Phase 2 preparations for MRT‑6160, and continued QuEEN discovery engine development .

Guidance Changes

MetricPeriodPrevious Guidance (Q2 2025)Current Guidance (Q3 2025)Change
Cash RunwayMulti‑year“into 2028” “through 2028” Raised/extended
MRT‑8102 (NEK7) Phase 1 Initial DataH1 2026H1 2026 H1 2026 (unchanged) Maintained
MRT‑6160 (VAV1) Phase 2 Initiation2025/2026Advancing toward multiple Phase 2 studies with Novartis Advancing toward multiple Phase 2 studies with Novartis Maintained
MRT‑2359 (GSPT1) Data2025Additional results in H2 2025 Additional results by year‑end 2025 Narrowed to YE25
CDK2/CCNE1 IND(s)2026IND submission(s) in 2026 IND submission(s) in 2026 Maintained
2nd‑gen NEK7 (CNS‑optimized) IND2026IND in 2026 IND in 2026 Maintained

Earnings Call Themes & Trends

Note: No Q3 2025 earnings call transcript was available. Themes reflect Q1–Q3 earnings materials and Q3 investor events.

TopicPrevious Mentions (Q1 & Q2 2025)Current Period (Q3 2025)Trend
Partnerships/BDNovartis MRT‑6160 deal ($150M upfront in 2024); Roche discovery collaboration Second Novartis agreement ($120M upfront; up to $5.7B total economics) Strengthening external validation and funding
AI/Technology (QuEEN engine)Featured in Science; expanding targetable space Reinforced as strategic differentiator; core to pipeline creation Consistent emphasis, growing visibility
Immunology pipeline (MRT‑6160/VAV1)Phase 1 data supported Phase 2 path; Novartis to lead Phase 2 Advancing toward multiple Phase 2s under Novartis sponsorship On track
Cardio‑immunology (MRT‑8102/NEK7)IND filed and first subjects dosed in Phase 1 (July) Phase 1 ongoing incl. high‑CVD risk cohort; AHA preclinical data highlighted NEK7 strategy On track; expanding external validation
Oncology (MRT‑2359/GSPT1)Focused on mCRPC; early PR/SD signals; H2’25 update planned Additional results planned by year‑end 2025 Near‑term catalyst
Liquidity/RunwayCash into 2028 Runway through 2028; added $120M upfront and October ATM proceeds Improved visibility

Management Commentary

  • “With three programs in clinical development and a highly productive drug discovery engine… our recently announced second collaboration with Novartis marks another major milestone… Our cash runway extends beyond multiple anticipated Phase 2 readouts for MRT‑8102, MRT‑6160, and MRT‑2359” — Markus Warmuth, CEO .
  • “We have recently initiated dosing a cohort of subjects with elevated cardiovascular disease (CVD) risk… Initial MRT‑8102 data… are on track for the first half of 2026” .
  • “Advancement of MRT‑6160 toward multiple Phase 2 studies in immune‑mediated diseases is ongoing, in collaboration with Novartis” .

Q&A Highlights

Note: No Q3 earnings call transcript available; highlights below reflect a September investor forum.

  • Novartis second collaboration rationale and impact: “We’ve entered into another collaboration with Novartis… a reflection of the mutual respect we have grown… excited to work on the next round of programs” .
  • VAV1 safety and TI: phase 1 healthy volunteer and tox data support a wide window: “At the highest dose… we didn’t see any toxicities… one of the cleanest tox reports… no tox concern whatsoever” .
  • NEK7 strategy and biomarkers: targeting upstream inflammasome assembly with CRP reduction benchmarks: “Bottom line is ~60%+ is our base case [CRP reduction]; 80%+ even more exciting” in high‑CVD risk cohort .
  • MRT‑2359 expansion: prostate cancer cohort expansion with goal to present data by year‑end; early PR/SD signals in resistant AR biology .
  • Cash/runway: “It was just below $300 million [in Q2]; runway into 2028… [new deal] is certainly going to extend our cash runway” .

Estimates Context

  • Street (S&P Global) modeled Q3 revenue at $7.37M and EPS at -$0.35, while actuals were $12.77M and -$0.33, respectively; revenue beat by ~73% and EPS by ~$0.02 (likely reflecting stronger collaboration revenue recognition) . Values retrieved from S&P Global.
  • Forward estimate considerations: non‑current deferred revenue increased to $111.9M at 9/30/25, consistent with the $120M Novartis upfront and indicating higher deferred revenue amortization in future periods as performance obligations are satisfied . Analysts may recalibrate collaboration revenue run‑rate and OpEx assumptions given accelerating clinical execution (higher R&D) .

Values with asterisks (*) retrieved from S&P Global.

Key Takeaways for Investors

  • Beat and raise on liquidity: substantial Q3 revenue/EPS beats, plus $120M upfront and ATM proceeds extend runway through 2028, reducing financing risk and supporting multi‑program execution .
  • Deferred revenue “banked”: step‑up in non‑current deferred revenue sets up a multi‑quarter tailwind to collaboration revenue recognition as obligations are delivered .
  • Clinical momentum: MRT‑6160 poised for multiple Novartis‑run Phase 2s; MRT‑8102 Phase 1 progressing with a biomarker‑rich high‑CVD risk cohort; MRT‑2359 data by YE25 is a key near‑term efficacy catalyst .
  • Near‑term trading setup: YE25 MRT‑2359 update and ongoing BD visibility (Novartis/Roche) are likely narrative drivers; absence of non‑GAAP metrics and sequential revenue variability may sustain volatility around quarter‑to‑quarter prints .
  • Medium‑term thesis: QuEEN engine plus expanding BD validates MGD platform; immunology (VAV1/NEK7) offers large market optionality while oncology (GSPT1, CCNE1/CDK2) diversifies risk .
  • Watch R&D cadence: OpEx will remain elevated as programs scale; balance sheet can support execution toward multiple proof‑of‑concept readouts through 2028 .
  • Risk checks: Collaboration revenue timing, clinical readouts (MRT‑2359 YE25; MRT‑8102 H1’26), and regulatory/indication selection under Novartis frameworks remain key de‑risking milestones .

Values with asterisks (*) retrieved from S&P Global.

Citations:

  • Q3 2025 8‑K/press release and financials ; companion press release ; AHA/ACR press releases .
  • Q2 2025 8‑K/press release .
  • Q1 2025 8‑K/press release and deck .
  • Investor forum transcript (Sept 2025) .